Cover Story
Regulatory News
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
In Brief
Clinical Roundup
Drugs & Targets
NCI Trials
NCI Trials for October 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer” - ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications - Jose and Irma Russo— husband and wife trailblazers in breast cancer research
- Sanya Springfield named NCI acting deputy director for health equity and inclusion
- PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends
- Karen Knudsen to leave ACS